Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications

British Journal of Psychiatry

Volumn 184, Issue SUPPL. 47, 2004, Pages

  Cavazzoni, Patrizia ^a   Mukhopadhyay, Nitai ^a   Carlson, Christopher ^a   Breier, Alan ^a   Buse, John ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG SCREENING; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MENTAL PATIENT; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; WEIGHT GAIN; ADOLESCENT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; META ANALYSIS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA;

EID: 1842684115     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.184.47.s94     Document Type: Conference Paper

References (52)

1. Allison, D. B., Mentore, J. L., Heo, M., et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 1686-1696.
2. American Diabetes Association (2001) Postprandial blood glucose. Diabetes Care, 24, 775-778.
3. American Diabetes Association (2002) Clinical Practice Recommendations. Position Statements: Screening for Diabetes. Diabetes Care, 25, S21-S24.
4. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn revised) (DSM-III-R). Washington, DC: APA.
5. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA.
6. Beasley, C. M., Sanger, T., Satterlee, W., et al (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 124, 159-167.
7. Beasley, C. M., Tollefson, G., Tran, P., et al (1996b) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111-123.
8. Brown, S., Birtwistle, J., Roe, L., et al (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29, 697-701.
9. Buse, J., Cavazzoni, P., Hornbuckle, K., et al (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology, 56, 164-170.
10. Caro, J. J., Ward, A., Levinton, C., et al (2002) The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. Journal of Clinical Psychiatry, 63, 1135-1139.
11. Chan, J. M., Rimm, E. B., Colditz, G. A., et al (1994) Obesity, fat distribution and weight gain as risk factors for clinical diabetes in men. Diabetes Care, 17, 961-969.
12. Colditz, G. A., Willett, W. C., Rotnitzky, A., et al (1995) Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine, 122, 481-486.
13. Croarkin, P. E., Jacobs, K. M. & Bain, B. K. (2000) Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics, 41, 369-370.
14. Dixon, L., Weiden, P., Delahanty, J., et al (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin, 26, 903-912.
15. Dunstan, D. W., Zimmet, P. Z., Welborn, T. A., et al (2002) The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) - methods and response rates. Diabetes Research and Clinical Practice, 57, 119-129.
16. Felker, B., Yazel, J. J. & Short, D. (1996) Mortality and medical morbidity among psychiatric patients: a review. Psychiatric Services, 47, 1356-1363.
17. Gianfrancesco, F. D., Grogg, A. L., Mahmoud, R. A., et al (2002) Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Journal of Clinical Psychiatry, 63, 920-930.
18. Harris, K. I., Flegal, K. M., Cowie, C. C., et al (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care, 21, 518-524.
19. Henderson, D. C. (2002) Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs, 16, 77-89.
20. Henderson, D. C., Cagliero, E., Gray, C., et al (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry, 157, 975-981.
21. Jeste, D. V., Gladsjo, J. A., Lindamer, L. A., et al (1996) Medical comorbidity in schizophrenia. Schizophrenia Bulletin, 22, 413-430.
22. Jin, H., Meyer, J. M. & Jeste, D. V. (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Annals of Clinical Psychiatry, 14, 59-64.
23. Koller, E. A. & Doraiswamy, P. M. (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy, 22, 841-852.
24. Koller, E., Schneider, B., Bennett, K., et al (2001) Clozapine-associated diabetes. American Journal of Medicine, 111, 716-723.
25. Koller, E. A., Cross, J. T., Doraiswamy, P. M., et al (2003) Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy, 23, 735-744.
26. Kornegay, C. J., Vasilakis-Scaramozza, C. & Jick, H. (2002) Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. Journal of Clinical Psychiatry, 63, 758-762.
27. Koro, C. E., Fedder, D. O., L'Italien, G. J., et al (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ, 325, 243.
28. Lage, M. J. & Kemner, J. E. (2002) Use of atypical antipsychotics and the incidence of diabetes: evidence from a claims database. Schizophrenia Research, 53, 166.
29. Lee, D. W., Fowler, R. B., Kadlubek, P. J., et al (2002) No significant difference in diabetes risk during treatment with typical versus atypical antipsychotics: results from a large observational study. Drug Benefit Trends, 14, 46-52.
30. Melamed, Y., Mazek, D. & Elizur, A. (1998) Risperidone treatment for a patient suffering from schizophrenia and IDDM. Canadian Journal of Psychiatry, 43, 956.
31. Meyer, J. M. (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry, 63, 425-433.
32. Mokdad, A. H., Ford, E. S., Bowman, B. A., et al (2000) Diabetes trends in the US: 1990-1998. Diabetes Care, 23, 1278-1283.
33. Mukherjee, S., Decina, P., Bocola, V., et al (1996) Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry, 37, 68-73.
34. Newcomer, J. W., Haupt, D. W., Fucetola, R., et al (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry, 59, 337-345.
35. Osborn, D. P. J. (2001) The poor physical health of people with mental illness. Western Journal of Medicine, 175, 329.
36. Phelan, M., Stradins, L. & Morrison, S. (2001) Physical health of people with severe mental illness. BMJ, 322, 444.
37. Procyshyn, R. M., Pande, S. & Tse, G. (2000) New-onset diabetes mellitus associated with quetiapine. Canadian Journal of Psychiatry, 45, 668-669.
38. Rolka, D. B., Narayan, K. M., Thompson, T. J., et al (2001) Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care, 24, 1899-1903.
39. Sernyak, M. J., Leslie, D. L., Alarcon, R. D., et al (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 159, 561-566.
40. Smith, R. C., Lindenmayer, J. P., Khan, M., et al (2002) A prospective cross-sectional of glucose and lipid metabolism with atypical and conventional antipsychotics. Biological Psychiatry, 51, 42S.
41. Sobel, M., Jaggers, E. D. & Franz, M. A. (1999) New-onset diabetes mellitus associated with the initiation of quetiapine treatment. Journal of Clinical Psychiatry, 60, 556-557.
42. Sowell, M. O., Mukhopadhyay, N., Cavazzoni, P., et al (2002) Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. Journal of Clinical Endocrinology and Metabolism, 87, 2918-2923.
43. Tabata, H., Kikuoka, M., Kikuoka, H., et al (1987) Characteristics of diabetes mellitus in schizophrenic patients. Journal of the Medical Association of Thailand, 70 (suppl. 2), 90-93.
44. Tollefson, G. D., Beasley, C. M., Tran, P., et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457-465.
45. Tollefson, G. D., Dellva, M. A., Mattler, C. A., et al (1999) Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. Journal of Clinical Psychopharmacology, 19, 435-443.
46. Tollefson, G. D., Birkett, M. A., Kiesler, G. M., et al (2001) Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biological Psychiatry, 49, 52-63.
47. Tran, P., Hamilton, S. H., Kuntz, A. J., et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychiatry, 17, 407-418.
48. Wang, P. S., Demier, O. & Kessler, R. C. (2002a) Adequacy of treatment for serious mental illness in the United States. American Journal of Public Health, 92, 92-98.
49. Wang, P. S., Glynn, R. J., Ganz, D. A., et al (2002b) Clozapine use and risk of diabetes mellitus. Journal of Clinical Psychopharmacology, 22, 236-243.
50. Wannamethee, S. G. & Shaper, A. G. (1999) Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care, 22, 1266-1272.
51. Wirshing, D. A., Pierre, J. M., Eyeler, J., et al (2001) Risperidone associated new-onset diabetes. Biological Psychiatry, 50, 148-149.
52. Yang, S. H. & McNeely, M. J. (2002) Rhabdomyolysis, pancreatitis and hyperglycemia with ziprasidone. American Journal of Psychiatry, 159, 1435.